Department of Pharmaceutical Sciences, University of Milan, via L. Mangiagalli 25, 20133, Milano, Italy.
Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, via A. Ferrata 9, 27100, Pavia, Italy.
Eur J Med Chem. 2022 Apr 15;234:114235. doi: 10.1016/j.ejmech.2022.114235. Epub 2022 Mar 5.
Mycobacterial resistance is a rapidly increasing phenomenon requiring the identification of new drugs effective against multidrug-resistant pathogens. The inhibition of protein tyrosine phosphatase B (MptpB), which interferes with host immune responses, may provide a new strategy to fight tuberculosis (TB), while preventing cross-resistance issues. On this basis, starting from a virtual screening (VS) campaign and subsequent structure elucidation studies guided by X-ray analyses, an unexpected γ-lactone derivative (compound 1) with a significant enzymatic activity against MptpB was identified. The structural characterization of compound 1 was described by means of NMR spectroscopy, HRMS, single crystal X-ray diffraction and Hirshfeld surface analysis, allowing a detailed conformational investigation. Notably, the HPLC separation of (±)-1 led to the isolation of the most active isomer, which emerged as a very promising MptpB inhibitor, with an IC value of 31.1 μM. Overall, the new chemotype described herein might serve as a basis for the development of novel treatments against TB infections.
分枝杆菌耐药性是一种迅速增加的现象,需要鉴定新的药物来对抗耐多药病原体。抑制蛋白酪氨酸磷酸酶 B(MptpB)可能为治疗结核病(TB)提供新策略,同时防止交叉耐药问题,因为它干扰了宿主的免疫反应。在此基础上,我们从虚拟筛选(VS)活动和随后的 X 射线分析指导的结构阐明研究开始,鉴定出一种具有显著 MptpB 酶活性的意想不到的γ-内酯衍生物(化合物 1)。通过 NMR 光谱、高分辨率质谱、单晶 X 射线衍射和 Hirshfeld 表面分析对化合物 1 的结构特征进行了描述,允许进行详细的构象研究。值得注意的是,(±)-1 的 HPLC 分离导致最活跃的异构体的分离,该异构体作为一种非常有前途的 MptpB 抑制剂出现,IC 值为 31.1 μM。总的来说,本文所述的新型化学型可能成为开发新型 TB 感染治疗方法的基础。